Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 19/20 | 1.00 |
| ▸ | PGR | P06401 | 15/20 | 1.00 |
| ▸ | AR | P10275 | 12/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21143406 | 1.00 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL20048206 | 0.93 | NR3C1 (0.87) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL19042673 | 0.92 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL23653772 | 0.91 | NR3C1 (0.88) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL20048092 | 0.91 | NR3C1 (0.88) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL20048416 | 0.90 | NR3C1 (0.82) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL20048418 | 0.89 | NR3C1 (0.87) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL26372430 | 0.89 | NR3C1 (0.81) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL20048212 | 0.88 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2C8 | |
| SCHEMBL30324808 | 0.88 | NR3C1 (1.00) | NR3C1PGRARCYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4653047-A2 | MIFEPRISTONE FOR USE IN IMPROVING INSULIN SENSITIVITY | Nieman, Lynnette K. (US) | 2025-11-26 | — | — | EP | claimed |
| US-20250281504-A1 | Method for improving insulin insensitivity | NIEMAN LYNNETTE K (US) | 2025-09-11 | — | — | US | claimed |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2024-06-11 | — | — | US | claimed |
| EP-4334314-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | Nuvation Bio Inc. (US) | 2024-03-13 | — | — | EP | claimed |
| CN-117580839-A | Anti-cancer nuclear hormone receptor targeting compounds | 诺维逊生物股份有限公司 | 2024-02-20 | — | — | CN | claimed |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-12-01 | — | — | US | claimed |
| WO-2022235585-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2022-11-10 | — | — | WO | claimed |
| US-20220288091-A1 | Method for Improving Insulin Sensitivity | NULYN SCIENCE S.A.S. (FR) | 2022-09-15 | — | — | US | claimed |
| EP-3941460-A1 | METHOD FOR IMPROVING INSULIN SENSITIVITY | Nieman, Lynnette K. (US) | 2022-01-26 | — | — | EP | claimed |
| US-20260014172-A1 | ABIRATERONE PRODRUGS | ASTELLAS US LLC (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4653047-A2 | MIFEPRISTONE FOR USE IN IMPROVING INSULIN SENSITIVITY | Nieman, Lynnette K. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250281504-A1 | Method for improving insulin insensitivity | NIEMAN LYNNETTE K (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250186463-A1 | ABIRATERONE DECANOATE PRODRUGS AND USE IN THERAPY | ASTELLAS US LLC | 2025-06-12 | — | — | US | disclosed |
| US-20250025417-A1 | ORAL ABIRATERONE FORMULATIONS | ASTELLAS US LLC | 2025-01-23 | — | — | US | disclosed |
| US-10472387-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| US-10472387-B2 | Inhibitors of glucocorticoid receptor | ORIC PHARMACEUTICALS, INC. (US) | 2019-11-12 | — | — | US | disclosed |
| WO-2019200156-A1 | SOLID FORMS AND FORMULATIONS COMPRISING A GLUCOCORTICOID RECEPTOR ANTAGONIST AND USES THEREOF | ORIC PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190218246-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| US-20190218246-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. | 2019-07-18 | — | — | US | disclosed |
| WO-2018068021-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | ORIC PHARMACEUTICALS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472387-B2 | Inhibitors of glucocorticoid receptor | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20220380364-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | NR3C1 20/4885PGR 28/4885AR 9/4885 |
| US-12006314-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NR5A1, NCOA1, NR5A2 | NR3C1 10/4885PGR 79/4885AR 4/4885 |
| US-20260014172-A1 | ABIRATERONE PRODRUGS | SHBG, CYP17A1, HSD17B11 | NR3C1 51/4885PGR 32/4885AR 5/4885 |
| US-20190218246-A1 | INHIBITORS OF GLUCOCORTICOID RECEPTOR | NR3C1, NR3C2, MC2R | NR3C1 1/4885PGR 59/4885AR 11/4885 |
| US-20250186463-A1 | ABIRATERONE DECANOATE PRODRUGS AND USE IN THERAPY | AR, CYP21A2, CYP17A1 | NR3C1 83/4885PGR 29/4885AR 1/4885 |
| US-20250025417-A1 | ORAL ABIRATERONE FORMULATIONS | CYP21A2, SHBG, CYP17A1 | NR3C1 27/4885PGR 145/4885AR 5/4885 |
| US-20220288091-A1 | Method for Improving Insulin Sensitivity | SHBG, GPR119, SERPINA6 | NR3C1 15/4885PGR 1532/4885AR 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.